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Dengue represents an important health problem in Brazil and therefore there is a great need to develop 
a vaccine or treatment. The neutralization of the dengue virus by a specific antibody can potentially be 
applied to therapy. The present paper describes, for the first time, the preparation of Immunoglobulin 
specific for the dengue virus (anti-DENV IgG), collected from screened Brazilian blood-donations. 
Production was performed using the classic Cohn–Oncley process with minor modifications. The anti-
DENV IgG was biochemically and biophysically characterized and fulfilled the requirements defined 
by the European Pharmacopoeia. The finished product was able to neutralize different virus serotypes 
(DENV-1, DENV-2, and DENV-3), while a commercial IgG collected from American blood donations 
was found to have low anti-dengue antibody titers. Overall, this anti-DENV IgG represents an important 
step in the study of the therapeutic potential and safety of a specific antibody that neutralizes the dengue 
virus in humans.
Uniterms:. Viral infections. Dengue/treatment. Dengue/virus/neutralization. Immunoglobulins/
preparation. Plasma fractionation. Virus neutralization.
A dengue representa um importante problema de saúde no Brasil, portanto, a identificação de vacina 
ou tratamento eficaz é uma necessidade urgente. A neutralização do vírus da dengue, por anticorpo 
específico, tem potencial aplicação terapêutica. Descrevemos aqui, pela primeira vez, a preparação 
de imunoglobulina específica para o vírus da dengue (IgG anti-DENV), produzida a partir do plasma 
selecionado de doadores brasileiros. A produção foi realizada utilizando o método clássico de Cohn-Oncley 
com pequenas modificações. A IgG anti-DENV foi bioquimicamente e biofisicamente caracterizada e 
cumpriu os requisitos definidos pela Farmacopeia Europeia. O produto final foi capaz de neutralizar 
diferentes sorotipos do vírus (DENV-1, DENV-2 e DENV-3), enquanto que a IgG comercial, produzida a 
partir do plasma de doadores americanos, apresentou baixos títulos de anticorpos anti-dengue. No geral, 
esta IgG anti-DENV representa uma importante etapa para o estudo do potencial terapêutico e segurança 
da neutralização, por anticorpos específicos, do vírus da dengue em humanos.
Unitermos: Infecções virais. Dengue/tratamento. Dengue/vírus/neutralização. Imunoglobulinas 
específicas/preparação. Fracionamento de plasma. Neutralização viral.
INTRODUCTION
There are around 2.5 billion people living in areas 
endemic for dengue fever and it is estimated that there 
are 100 million infections annually (Gubler 1998). The 
burden of dengue in endemic countries weighs heaviest 
on children. However, there has been an increasing trend 
towards adult infection in certain countries (Ooi, Goh, 
Gubler, 2006; Cummings et al., 2009). Most travelers with 
dengue have been adults (Wilder-Smith, Schwartz, 2005). 
Currently, neither cure nor vaccines are available, and new 
therapies are thus urgently needed. Although there have 
been considerable developments in medicinal chemistry, 
no promising small-organic compounds endowed with 
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virus inhibition activity have emerged (Yin et al., 2009). 
Passive transfer of specific antibodies is thus the most 
promising way of treating viral infections in such a way 
as to promote speedier patient recovery.
The dengue virus belongs to the Flaviviridae family 
and there are four known serotypes: DENV-1, DENV-2, 
DENV-3, and DENV-4. All four virus serotypes cause a 
spectrum of illness ranging from asymptomatic or mild 
febrile disease to classical dengue fever (DF) and to more 
severe disease manifesting as dengue hemorrhagic fever 
(DHF) and dengue shock syndrome (DSS) (Souza et al., 
2009). The severity of the disease is likely to depend on 
various factors, including the strain and serotype of the 
infecting virus, the age and genetic background of the 
patient and the degree of viremia (Guzman, Kouri, 2002; 
Vaughn et al., 2000). Many prospective, population-based 
cohort and clinical studies have established secondary 
infections with a heterotypic dengue virus serotype 
as a major risk factor for severe disease. Antibody-
dependent enhancement (ADE) involves the boosting of 
virus replication in Fc-receptor bearing cells (especially 
monocytes and macrophages) by way of pre-existing, 
non-protective levels of cross-reactive dengue antibodies. 
It is postulated that ADE results in an amplified cascade of 
cytokines and complement activation causing endothelial 
dysfunction, platelet destruction, and consumption of 
coagulation factors, which result in plasma leakage and 
hemorrhage (Halstead, 1979, 2003).
DENVs have given rise to large outbreaks in Brazil 
in the past 25 years with more than 5 million reported 
cases. (Figueiredo, 2010). Given that approximately 50% 
of DENV-infected individuals remain asymptomatic, 
and that the duration of viremia prior to the onset of 
symptoms is estimated at 1 to 2 days, it is possible that 
viremic individuals donate blood and serve as a source of 
dissemination of the virus in the community (Mohammed 
et al., 2008; Linnen et al., 2008; Tambyah et al., 2008; 
Chuang et al., 2008; Nishiura, Halstead, 2007). The first 
epidemic of dengue fever in Brazil, with isolation of the 
virus, occurred in 1981, in the State of Roraima, where 
DENV-1 and DENV-4 were identified (Osani et al., 1983). 
In 1986, DENV-1 was identified in the State of Rio de 
Janeiro (Nogueira et al., 1988) and subsequently spread 
to other States in Brazil.
P o l y v a l e n t  ( i . e .  n o r m a l )  i n t r a v e n o u s 
immunoglobulins G (IVIGs) are collected from 1,000 to 
10,000 healthy blood-donors. The first therapeutic use of 
polyvalent IgGs was for antibody replacement therapy 
(Orange et al., 1949). However, many other clinical 
benefits of IVIGs have been demonstrated. They have 
been used for bone marrow and organ transplantation, to 
treat chronic inflammatory demyelinating polyneuropathy, 
severe asthma, pediatric HIV, dermatomyositis, idiopathic 
thrombocytopenic purpura as well as multiple sclerosis 
(Achiron et al., 1998; Achiron et al., 2000; Brennan, 
2001; Dalakas et al., 1993; Hann et al., 1996; Lories 
et al., 2000; Ohlsson, Lacy, 2001). Different from the 
polyvalent IVIGs, for the production of specific IVIG 
(i.e., hyper-immune), intact IgG are collected from the 
plasma of blood-donors previously identified as having 
high levels of a specific antibody or at least a population of 
similar antibodies. Examples are the Hepatitis B, tetanus, 
cytomegalovirus, or rabies anti-IgGs (Atkins et al., 2000; 
Gelfand, 2001). The most classic examples of specific 
IVIG are the anti-D IgG (Rho) and anti-hepatitis B IgG 
(Okwundu, Afolabi, 2013).
Given this, it is still not known what implications 
might arise from a treatment based on IVIG prepared 
from Brazilian blood-donors (anti-dengue antibodies) 
for neutralizing the virus. Another question is that of 
whether specific anti-dengue IVIG preparation is efficient 
and safer for dengue treatment. To date, no anti-dengue 
IVIGs collected from a pool of blood-donors have been 
produced. To address this, the present study describes 
the plasma screening, fractionation and biochemical 
validation of anti-dengue IgG prepared from a plasma 
pool of Brazilian blood donors. Among the procedures 
available for producing specific anti-IgGs in a laboratorial 
scale, we choose the classic Cohn-Oncley protocol 
(Lucena et al., 2010). The production process here also 
includes two dedicated virus clearance steps, being thus a 
combination of the currently used Cohn–Oncley protocol 
with modifications.
MATERIAL AND METHODS
Plasma selection
A plasma pool from blood-donations received at the 
Pernambuco Hematology and Hemotherapy Foundation 
- HEMOPE (in the State of Pernambuco, in the Northeast 
Region of Brazil) was collected and the plasma bags 
considered free of contamination were selected. Once 
the contamination-free plasma bags were selected, the 
plasma rich in anti-dengue IgG was separated. To this end, 
a commercial ELISA kit (E-DEN01G panbio diagnostics, 
Cheshire, UK) was used for the indirect measurement of 
anti-dengue antibodies. This ELISA kit adsorbs dengue 
antigens on the plate and ELISA reveals them using 
horse peroxidase in combination with anti-human IgG. 
This ELISA kit was also used on plasma without the anti-
dengue IgG (the negative control).
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Immunoglobulin fractionation
The IgG was precipitated out from the crude 
plasma using the Cohn-Oncley process (cold ethanol 
precipitation) with minor modifications. The general 
process is depicted in Figure 1. The process of cold ethanol 
precipitation is based on tuning the protein solubility by 
adjusting pH, temperature, salt concentration, and ethanol 
(Cohn et al., 1946). In short, the frozen plasma is thawed 
until it reaches 4 °C, at which temperature fibrinogen and 
clotting factor VIII are insoluble and are precipitated out. 
The cryo-precipitate is then removed by centrifugation and 
the cryo-free plasma is treated using Method 6 from Cohn 
et al. (1946). Fibrinogen was precipitated in fraction I and 
immunoglobulin was separated off from albumin by II + 
III precipitation. The precipitates were separated from the 
supernatants by centrifugation.
In accordance with Oncley et al. Method 9 (1949), 
fraction II + III was suspended and fraction III was 
separated off. The supernatant was clarified by depth 
filtration with the aid of a filter. From this filtrate, an IgG 
paste was obtained and collected by centrifugation. The 
IgG paste was then dissolved in sterile water for injection 
and clarified by depth filtration with the aid of a filter.
To reduce the ionic forces, the solution was filtered 
through ultrafiltration membranes (diafiltration) with sterile 
water for injection, followed by protein concentration 
adjustment to 5% (w/v). A 30 kD Millipore Pellicon 
Systen was used to perform diafiltration and protein level 
adjustment. Virus inactivation was performed using a 
solvent (tri-n-butyl phosphate; TNBP) and a detergent 
(Tween 80) (Horowitz et al., 1985). To remove the solvent 
and detergent, a cation-exchange chromatography using 
a CM Sepharose FF stationary phase was performed. Yet 
to remove immunoglobulin A and other components, an 
anion-exchange chromatography in DEAE Sepharose 
FF was carried out. The flow-through was concentrated 
by ultrafiltration (10 KD Millipore Pellicon System) and 
diafiltered with 0.25 mol/L glycine using the same system. 
The protein level was adjusted to 5% (w/v) and pH to 
4.2-4.3. Sterilizing filtration was performed and the final 
solution packaged aseptically. To inactivate virus particles, 
the final product was incubated at 23-27 °C for 21 days 
before stock at 2-8 °C.
Product validation
To check the functional properties of the product 
during the process and of the final preparation, we 
performed the protocols established by the European 
Pharmacopoeia and described in product marketing 
FIGURE 1 - Purification process for anti-dengue specific IgGs 
(Oncley et al., 1949; Lucena et al., 2010).
authorization dossiers approved by National Regulatory 
Authorities. Distribution of molecular size was analyzed 
using size exclusion chromatography with a Biosep 
SEC-S3000 (600 x 7.8 mm) column (Phenomenex). 
Radial immune diffusion was used to determined IgM 
and subclass distribution of IgG. Enzyme-Linked 
Immunosorbent Assay (ELISA) was used to measure IgA 
and IgE and check the absence of antibodies screened for 
blood donation, such as Human Immunodeficiency Virus 
(HIV1, HIV2), hepatitis B surface antigens (HBsAg), 
Hepatitis C (HCV), Human T lymphotropic virus (HTLV), 
Chagas disease and syphilis.
Cellulose acetate electrophoresis was used to measure 
γ-globulin. The methods used for the determination 
of pyrogen and anticomplementary activity were in 
accordance with European Pharmacopoeia monographs 
2.6.8 and 2.6.17, respectively. A thermostability assay 
was performed by incubation of the preparation at 57 °C 
for 4 hours.
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Identification of anti-dengue serotypes
To ascertain the broad neutralizing properties of the 
anti-dengue IgG described here, the neutralizing action 
of IgG was measured for different isolated serotypes. 
Isolated serotypes DENV-1 (PE/97-42735), DENV-2 
(PE/95-3808), and DENV-3 (PE/02-95016) were supplied 
by the Central Laboratory of Pernambuco (LACEN-PE, 
Brazil). In this experiment, a commercial polyvalent IVIG 
(Kiovig/ Baxter International Inc, Deerfield, IL, USA) was 
also used. Anti-dengue antibodies for different dengue 
serotypes were measured using the Plaque-Reduction 
Neutralization Test (PRNT) (Morens et al., 1985).
First, a two-fold serial dilution of IgG (1/20 
to 1/2.560) in Minimum Essential Medium (MEM) 
(Invitrogen) was placed in 96-well microtiter plates to a 
final volume of 100 µL. Then, 100 µL of a viral suspension 
(30 plaque forming units/mL) of DENV-1 (PE/97-42735), 
DENV-2 (PE/95-3808), and DENV-3 (PE/02-95016) 
was aliquoted into the respective wells. The plate was 
incubated for 1 hour at 37 oC in 5% CO2. Then, 50 µL of 
the IgG/virus mixture was collected from each dilution 
and transferred into a 24 well-plate containing Vero cells 
previously seeded at a density of 3x106 cells/mL, in MEM 
supplemented with 10% Fetal Calf Serum (FCS, GIBCO). 
After virus attachment (incubation for 1 hour at 37 oC in 
5% CO2), each well was covered with 500 µL of MEM 
10X medium, supplemented with 10% FBS, 1% penicillin/
streptomycin and 3% carboxymethylcellulose. The plate 
was then incubated for 7 days at 37 °C in 5% CO2. To 
inactivate the virus particles, the medium was removed 
and the monolayer cells covered with formalin (solution at 
3.5 M, 2 mL per well) and incubated for 1h. The formalin 
solution was washed out and the cells were stained with 
crystal violet (1:50 v/v, 0.5 mL per well). The number 
of regions of infected cells (plaques) was counted and 
compared to the virus particles receiving only polyvalent 
IVIG and the non-treated virus particles.
Ethics statement
The study protocol was approved by the HEMOPE 
ethics committee (process number 002/2011). Patients were 
not identified and study data was analyzed anonymously.
RESULTS AND DISCUSSION
In Table I, we summarize the biochemical and 
biophysical properties of the anti-dengue IgG. The 
parameters showed in Table I are defined by European 
Pharmacopoeia and described in product marketing 
authorization dossiers approved by National Regulatory 
Authorities.
Electrophoresis showed a satisfactory level of purity 
with 98% of proteins migrating to the gamma region. IgG 
subclass content in this preparation was found to be similar 
to naturally occurring ratios (Morell et al., 1972).
The specific IVIG produced contained traces of IgA 
and IgM, immunoglobulins being mainly removed by 
cation-exchanged and anion-exchanged chromatographs 
respectively. Some authors have pointed out that the 
administration of IVIG preparations with significant 
amounts of IgA can cause severe anaphylactic reactions in 
patients with IgA deficiency (Vyas et al., 1968; Bjorkander 
et al., 1987).
The total number of aggregates present in the 
preparation lies within the acceptable range. IgG 
dimerization and aggregate formation was also associated 
with an increase in the risk of adverse effects (Kroez et 
al., 2003). These aggregates bind and activate components 
of the complementary system and routine determination 
of anticomplementary activity was therefore adopted. 
In the IVIG produced, consumption of the complement 
was not greater than 50%, as required by the European 
Pharmacopoeia. The product was kept at pH 4.0 – 4.5, 
which is optimal for maintaining IgG in an unaggregated 
state (Gelfand, 2006). Initially developed to produce a 
stable IgG solution, a low pH formulation was also used 
to achieve a final step involving inactivation of the virus.
Two steps were taken to inactivate the virus: solvent/
detergent (S/D) treatment and incubation at low pH. 
S/D treatment is very effective against lipid-enveloped 
viruses (Uemura et al., 1994; Chang et al., 2000). Low 
pH incubation also provides robust inactivation of lipid-
enveloped viruses, including HIV (Bos et al., 1998; 
Omar et al., 1996; Biesert, 1996; Reid et al., 1988). 
This product responds negatively (i.e. is non-reactive) 
to HBsAg, HCV, HIV1 and HIV2 antibodies, Chagas 
disease and syphilis. These are important biochemical 
characterizations, ensuring that the IgG is suitable for 
intravenous administration in subjects.
Completing biochemical and biophysical analysis, 
we examined the overall stability of this IgG preparation 
by way of thermo-stability. We did not observe alterations, 
such as gelification or flocculation. Therefore, the 
IVIG formulated in 0.25 mol/L glycine demonstrated 
appropriate osmolality.
Once the anti-dengue IgG was carefully characterized 
in terms of biophysical and biochemical properties, we 
decided to quantify the ratio of IgG serotypes for DENV-1, 
DENV-2, and DENV-3. DENV-4 was not tested. Table II 
presents these data. This product was found to have high 
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TABLE I – Anti-dengue IgG characterization
Test Reference values Results
pH(a) 4.0 – 7.4 4.3
Total protein(b) 45 – 55 mg/mL 51 mg/ mL
Protein composition(c) Minimum of 95% gammaglobulin 98%
Distribution of molecule size(c) Minimum of 90% monomer and dimer 
Maximum of 3% polymers and aggregates
98.1% 
1.1%
IgA  - 0.16 mg/mL
IgM  - 0.10 mg/mL
Subclass distribution Percent Percent
IgG1 65 – 70 68
IgG2 20 – 25 19
IgG3 7 – 10 7
IgG4 3 – 6 6
Anticomplementary activity (%) ≤ 50 39
Thermo stability (57 °C/4h) No gelification No gelification
Antibody to hepatitis B surface antigen (d) Minimum 0.5 IU/g 1.24 IU/g
Pyrogen (e) Absence Absence
(a) Analyzed by fluorescamine standard curve. (b)Determined by Kjeldahl method. (C) Determined by electrophoresis. (d) By using 
ELISA kit assays against hepatitis. (e) Determined by using detection kit and analyzed by PCR.
TABLE II - Dengue antibody titers of the specific immunoglobulin 
preparation by plaque reduction
Sample*
antibodies
DENV-1 DENV-2 DENV-3
Crude plasma 1:160 1:640 1:40
Anti-dengue IgG 1:160 1:1280 1:160
Trademark (Kiovig) 1:40 1:40 < 1:20 (negative)
*Experiments were repeated at least three times independently. 
The data here present the mean for one single experiment.
anti-dengue antibody titers of 1:1280 for DENV-2 and 
1:160 for DENV-1 and DENV-3. This was expected, since 
this IVIG was prepared using blood donations from Brazil, 
which is an endemic area (Cordeiro et al., 2007). In Brazil, 
three serotypes are currently in circulation, DENV-1, 2, 
and 3, while infection by DENV-4 is more restricted to 
the North Region (Roraima, Manaus and Belém) (Brazil, 
2010, 2011a, 2011b). The broad neutralizing property 
in relation to the different virus types confirmed the 
functional activity of this IgG product. The commercial 
IVIG (prepared from American blood donations, brand 
Kiovig/ Baxter) was found to have low titers for DENV.
Several preparations of IVIG are now available for 
therapy, however it is well known that different plasma 
sources may influence the immunological composition of 
IVIG. In clinical practice, different preparations of IVIG or 
different batches may result in variable beneficial effects. 
For a biological study, it is therefore very important to 
describe the reasons for choosing a preparation of IVIG 
and to consider the specific characteristics of the product 
that are relevant to a particular clinical response (Elluru et 
al., 2006; Gelfand, 2006; Gürcan, Keskin, Ahmed, 2010).
The knowledge of virology gathered over the 
years suggests that specific IVIGs are useful for virus 
neutralization. This is the case for hepatitis B and for the 
arbovirus West Nile virus (WNV). If we compare dengue 
and WNV, both infections are immunologically and 
pathogenically similar to each other and have a similar 
infection course. It has also been reported that specific 
anti-WNV IgGs are efficient in reducing virus titers in 
patients severely-infected with WNV (Saquib et al., 2008; 
Wadei et al., 2004; Haley et al., 2003). In pre-clinical 
studies, anti-WNV IgGs substantially reduced mortality in 
WNV-infected mice. In contrast, the mortality is observed 
in WNV-infected mice when a polyvalent is administered 
instead of specific IgG (Ben-Nathan et al., 2003). In light 
of these findings, investigation of the potential of specific 
human anti-dengue IgG would appear to be a reasonable 
proposition.
The feasibility of a Brazilian IVIG, with anti-dengue 
antibody titers for treatment of dengue-patients, would 
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involve the same approach currently employed for patients 
with WNV (Saquib et al., 2008; Wadei et al., 2004; Haley 
et al., 2003). However, the safety of using this type of 
preparation in dengue-patients should be confirmed. The 
pre-existence of heterologous antibodies, in the presence 
of a new infection by a distinct serotype may cause 
ADE (Gubler, 2002; Guzmán, Kouri, 2004; Ross, 2010; 
Wilder-Smith et al., 2005). Since all four serotypes exist 
in Brazil, further studies are necessary to confirm whether 
a treatment based on Brazilian IVIG is safe for dengue-
patients or may cause ADE.
CONCLUSION
The present study has described, for the first time, 
the production and biophysical/biochemical validation of 
a human anti-dengue IVIG prepared using Brazilian blood 
donations. The product was characterized in regarding to 
its immunoglobulin composition, biophysical parameters, 
purity and capacity to neutralizing Dengue antibodies. As 
expected, this anti-Dengue IgG preparation exhibited higher 
titers of anti-dengue antibodies than a trademark product, 
which is produced by plasma of donors living in non-
endemic Dengue areas. The anti-dengue IVIG described 
here is useful for investigating the effect of anti-dengue 
IVIG during infection and its potential therapeutic use.
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LIST OF ABBREVIATIONS
ADE - Antibody-Dependent Enhancement, DENV 
– Dengue Virus, DF - Dengue Fever, DHF - Dengue 
Hemorrhagic Fever, DSS - Dengue Shock Syndrome, 
ELISA - Enzyme-Linked Immunosorbent Assay, FCS - 
Fetal Calf Serum, HBsAg - Hepatitis B Surface Antigens, 
HCV - Hepatitis C Virus, HEMOPE - Hematology and 
Hemotherapy Foundation of Pernambuco, HIV - Human 
Immunodeficiency Virus, HTLV - Human T Lymphotropic 
Virus, IVIG - Intravenous Immunoglobulins G, LACEN-
PE - Central Laboratory of Pernambuco, MEM - 
Minimum Essential Medium, PRNT - Plaque-Reduction 
Neutralization Test, Rho - Anti-D IgG, S/D - Solvent/
Detergent, TNBP - Tri-n-Butyl Phosphate, WNV - West 
Nile virus.
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